Tweets
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
What to do next? Dazodalibep Rx in bDMARDs IR #RA pts. Dazo is a novel CD40 ligand antagonist Phase II RCT. N=78, multi dose phase II RCT. All doses improved DAS28. Dosing interval may be prolonged over time. Awaiting phase 3. Abst#2008 #ACR22 @RheumNow https://t.co/IrzflycKZp
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
#abst2132 #acr22 @rheumnow safety of Deucravacitinib Ph2PsA&ph3PSO trial: no Δ from BL in hematology, chemistry, or lipid labs. JAK 1/2/3 Effects on hem, hepatic, CPK, and cholesterol lab parameters not observed over 16 wks of DEUC at doses up to 12 mg QD & in combo w/csDMARDs. https://t.co/bjGEYp4GcJ
Olga Petryna @DrPetryna ( View Tweet )
3 years 8 months ago
Hoffmann-Vold et al. SSc ILD frequently progresses even in long-standing SSc. Not just a disease of early SSc! @RheumNow #ACR22 Abstr#1536 https://t.co/nKiY2xFxfk https://t.co/W7SDm6QFpQ
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Ghaffar et al. Chronic abdominal periaortitis. Imaging improved in only 57% and resolved in 9%. Incident aneurysms rare 8%. Older age and secondary cause assoc greater likelyhood improvement, smokers 2 times less likely. @RheumNow #ACR22 Abstr#1576 https://t.co/jS9djx3ZtU https://t.co/OFW2Jk7gGW
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
13S150. Draft ACR/EULAR APLS Classif Crit #ACR22
Entry: Clinical & +aPL w/in 3 yr
Then: Additive crit
-Don't count other cause
Clinical Domains: Macrovasc VTE, Macrovasc AT, Microvasc, Obst, Cardiac, Hematology
Lab: +LA, aCL/B2GP IgM/IgG/titer
Total: 3+ clin, 3+ lab
@RheumNow https://t.co/YeKW0orjZC
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
⬆️ serum anti-CCP3 Ab, absence IA
👉 StopRA trial - ironically stopped🛑
❌ hydroxychloroquine not superior to PBO in preventing/ delaying IA
👉rate of conversion to RA in CCP3+ve ~35% @ 3yrs
#ACR22 @RheumNow Abst#1604
Patricia Harkins @DrTrishHarkins ( View Tweet )
3 years 8 months ago
“As long as you are practicing rheumatology, your legal risk is low.” - @greerdonley, law professor, on how rheumatologists should not let fear of legal consequences interfere w/practicing high quality evidenced based medicine for our patients #ReproductiveRheum #ACR22 @rheumnow
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
Makol @AshimaMakol et al. Multimorbidity in SSc . SSc higher burden multimorbidity at diagnosis and higher risk of developing multimorbidity over time @RheumNow #ACR22 Abstr#1190 https://t.co/VopFI6U5G5 https://t.co/hKKPC7v8EN
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxSpA who discontinued a first line TNFi. @RheumNow
https://t.co/fKDa5kPfXN https://t.co/CtMCj2Ihgc
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Mazareeb et al. von Willebrand Factor in systemic vasculitis. Increased in active vasculitis compared to remission and HCs. Correlates disease activity. Not affected by IL6i. @RheumNow #ACR22 Abstr#1573 https://t.co/uJAFHQpOlu https://t.co/PNX0puOeCn
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Drop PJP prophylaxis in #SLE. Retrospec cohort 4900 SLE on MMF or CYP: 1 case of PJP detected over 2282 person years (incidence rate 0.44/1000 py); PJP prophylx cause neutropenia (IRR 4.7), leukopenia (IRR 4.0), C diff (IRR 3.9), hyperkalemia (IRR 3.7) abst#1594 ACR#22 @rheumnow
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
